Discovering State-of-the-Art Novel Targets & Biomarkers to Propel New Approvals for the High Unmet Need in Hearing Disorders

The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss.

However, in a space that has also had to battle with multiple clinical failures, there’s a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval.

That’s why the 3rd Inner Ear Disorders Therapeutics Summit returned this summer, bringing together the community to collectively accelerate the development of drug-based approaches, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets.

This meeting leveraged the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear.